课题基金 / 基金详情

RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS

RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS
RO32 3555 托卡德治疗类风湿性关节炎的结构性关节损伤
批准号：
6265168
负责人：
MICHAEL H WEISMAN
金额：
$1.15万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6265168
关键词：
antirheumatic agents clinical research combination chemotherapy corticosteroids disabling disease disease /disorder prevention /control dosage drug screening /evaluation human subject human therapy evaluation imidazole joint disorder methotrexate nonsteroidal antiinflammatory agent pharmacokinetics quality of life rheumatoid arthritis sign /symptom

项目摘要

项目成果

MICHAEL H WEISMAN的其他基金

相似基金

相关文献

中文摘要
翻译
确定TROCADE与甲氨蝶呤背景抗风湿治疗相比预防关节结构损伤的最佳有效剂量，确定TROCADE是否可改善或稳定临床体征和症状、残疾或生活质量，确定TROCADE的安全性，并研究TROCADE与甲氨蝶呤背景治疗联合或不联合NSAID给药时的药代动力学，或皮质类固醇
英文摘要
Determine the optimal efficacious dose at which TROCADE when administered against background anti-rheumatic therapy of methotrexate prevents structural damage to articular joints, determine if TROCADE can provide improvement or stabilization of clinical signs and symptoms, disability or quality of life, determine safety of TROCADE and investigate the pharmacokientics of TROCADE when administered against a background therapy of methotrexate with or without NSAIDs or corticosteroids.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RECOMBINANT HUMAN INTERLEUKIN ELEVEN IN RHEUMATOID ARTHRITIS
STUDY OF ORAL CCII IN TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS
INDUCTION COURSE & MAINTENANCE CYCLE OF AG4263 IN RHEUMATOID ARTHRITIS
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
海外基金